[
    [
        {
            "time": "2021-02-04",
            "original_text": "贝达药业(300558.SZ)发行境外上市外资股(H股)申请获证监会受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "首发申请",
                    "证监会受理"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)发行境外上市外资股(H股)申请获证监会受理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "贝达药业：H股首发申请获证监会受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "H股",
                    "首发申请",
                    "证监会受理"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：H股首发申请获证监会受理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "午间公告2021年2月4日星期四",
            "features": {
                "keywords": [
                    "午间公告",
                    "2021年2月4日"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "午间公告2021年2月4日星期四",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 2,
                "Duration": 1,
                "Entity_Density": 1,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 3,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-02-04",
            "original_text": "贝达药业(300558.SZ)：赴港上市申请获中国证监会受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "赴港上市",
                    "证监会受理"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：赴港上市申请获中国证监会受理",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]